NCT05194995 2026-03-16
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Allist Pharmaceuticals, Inc.
Phase 1/2 Active not recruiting
Allist Pharmaceuticals, Inc.
National Cancer Institute (NCI)